Galapagos Successfully Completes First Phase I Study for GLPG0259
News Aug 06, 2009
Galapagos NV announces the successful completion its first-in-human trial of the novel candidate drug GLPG0259 for rheumatoid arthritis (RA). The candidate drug showed good safety in healthy volunteers and pharmacokinetic (PK) profile thus far, which supports once-daily oral dosing.
GLPG0259 is a novel mechanism-of-action inhibitor of the protein kinase MAPKAPK5, which was discovered through Galapagos' target discovery platform and represents a new approach for the treatment of RA.
The goal of the first-in-human trial was to determine the safety, tolerability, and pharmacokinetics of the candidate drug GLPG0259. The double blind, single ascending and multiple dose study was conducted in 34 healthy volunteers in Belgium from March to May 2009.
The compound was administered up to five consecutive days and showed good safety, with no cardiovascular side effects. The desired PK profile obtained thus far supports once-daily oral dosing.
"We are encouraged by the positive outcome of the first human trial for a candidate drug derived from Galapagos' target discovery platform," said Onno van de Stolpe, CEO of Galapagos. "We are on track to complete the Phase I trials for GLPG0259 by the end of 2009. Furthermore, preparations are underway to start a Phase IIa study in 2010, where we will assess the efficacy of this novel mechanism of action candidate drug in treating RA patients."
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018